Estimations des analystes de Wall Street pour PTC Therapeutics, Inc. (PTCT): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.29 | ||
| 2026-07-30 | $0.92 | $0.24 | +289.3% |
| 2026-05-07 | $-0.03 | $-0.45 | +93.3% |
| 2026-02-19 | $-1.67 | $-0.21 | -695.2% |
| 2025-11-04 | $0.20 | $-1.19 | +116.8% |
| 2025-08-07 | $-0.83 | $-1.07 | +22.4% |
| 2025-05-06 | $10.04 | $-1.08 | +1029.6% |
| 2025-02-27 | $-0.85 | $-1.12 | +24.1% |
Ratios de valorisation
| Prix / Valeur comptable | -33.74 |
| EV / EBITDA | 30.47 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $82.7M | $194.4M | $264.7M | $307.0M | $380.8M | $538.6M | $698.8M | $937.8M | $806.8M | $1.73B |
| Coût des Ventes | $117.6M | $4.6M | $12.7M | $12.1M | $18.9M | $32.3M | $44.7M | $65.5M | $57.4M | $71.8M |
| Marge Brute | -$34.9M | $189.8M | $252.1M | $294.8M | $361.8M | $506.3M | $654.1M | $872.3M | $749.4M | $1.66B |
| R&D | $117.6M | $117.5M | $172.0M | $257.5M | $477.6M | $540.7M | $651.5M | $666.6M | $534.5M | $455.2M |
| Frais Généraux | $97.1M | $121.3M | $153.5M | $202.5M | $245.2M | $285.8M | $326.0M | $332.5M | $300.9M | $347.1M |
| Charges Opérationnelles | $214.8M | $254.1M | $348.4M | $536.0M | $793.6M | $880.7M | $1.10B | $1.31B | $1.05B | $802.4M |
| Résultat Opérationnel | -$132.1M | -$64.3M | -$115.7M | -$241.2M | -$431.8M | -$374.4M | -$447.4M | -$439.5M | -$302.6M | $856.5M |
| EBITDA | -$128.8M | -$46.6M | -$89.5M | -$195.3M | -$303.1M | -$368.2M | -$367.8M | -$330.3M | -$120.5M | $887.7M |
| Charges d'Intérêt | $8.3M | $12.1M | $12.6M | $12.5M | $56.4M | $86.0M | $90.9M | $129.2M | $167.0M | $152.2M |
| Résultat Avant Impôts | -$141.5M | -$77.7M | -$128.1M | -$239.9M | -$402.9M | -$518.3M | -$587.5M | -$696.1M | -$363.1M | $696.6M |
| Impôts | $569000 | $1.3M | -$29000 | $11.7M | $35.2M | $5.6M | -$28.5M | -$69.5M | $176000 | $14.0M |
| Résultat Net | -$142.1M | -$79.0M | -$128.1M | -$251.6M | -$438.2M | -$523.9M | -$559.0M | -$626.6M | -$363.3M | $682.6M |
| BPA | $-4.17 | $-2.02 | $-2.75 | $-4.27 | $-6.64 | $-7.43 | $-7.79 | $-8.37 | $-4.73 | $8.58 |
| BPA Dilué | $-4.17 | $-2.02 | $-2.75 | $-4.27 | $-6.64 | $-7.43 | $-7.79 | $-8.37 | $-4.73 | $7.78 |
| Actions en Circulation (Diluées) | $34.0M | $39.2M | $46.6M | $58.9M | $66.0M | $70.5M | $71.7M | $74.8M | $76.8M | $88.3M |
Prix
| Prix | $67.35 |
| Capitalisation | $5.6B |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ACLX · ALKS · ARWR · CRNX · KRYS · MTSR · PCVX
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de PTCT: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions